S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
Status:
Completed
Trial end date:
2000-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic
amyloidosis.
PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in
treating patients who have primary systemic amyloidosis.
Phase:
Phase 2
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Cancer and Leukemia Group B National Cancer Institute (NCI)